Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of presbyopia, according to press releases from Opus Genetics and Viatris.
“Phentolamine is designed to improve near vision by modulating the iris to support a smaller pupil in a controlled, functional range,” George Magrath, MD, MBA, MS, CEO of Opus Genetics, told Healio. “This extends the depth of focus while aiming to preserve a natural visual experience. … Opus is advancing it specifically for presbyopia with a formulation and development program tailored